Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: Systematic analysis for the Global Burden of Disease Study 2019

Tian, Yiqun; Yang, Jin-Cui; Hu, Junjie; Ding, Rong; Ye, Dawei; Shang, Jiwen

doi:10.3389/fpubh.2023.1119374

Cited by 25 publications

(22 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Meanwhile, PC mortality decreased, indicating technologies on screening, diagnosis, and treatment were improving. (12,13) The reason for this rising trend of PC incidence and prevalence is in various aspects, which might include greater longevity and population aging, increasing disease risks associated with economic growth, the widespread of PC screening, especially prostate-speci c antigen (PSA) testing, and the improvement of cancer registries. (14)(15)(16)(17) The European Region and Region of the Americas had the highest DALYs rate of PC from 1990 to 2019, while the DALYs rates of PC in the WPR, by contrast, were relatively low except in Australia.…”

Section: Discussionmentioning

confidence: 99%

Disparities in the burden of prostate cancer and its trends in the Western Pacific Region, 1990-2019

Yang¹,

Zhou²,

Zhang³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Prostate cancer's (PC) burden and its temporal trend have been poorly studied. This study aimed to fill this gap by evaluating regional disparities of PC burden and trends in China, the Western Pacific Region (WPR), and the World from 1990 to 2019. Methods According to the estimation of prostate cancer disease burden in the global burden of disease 2019 (GBD 2019), we applied GBD 2019 analytical tools to compare PC incidence, mortality, prevalence, the years lived with disability (YLDs), years of life lost (YLLs) and disability-adjusted life-years (DALYs) from 1990 to 2019 in China, the WPR, and the World. Disease burden trends between 1990 and 2019 were evaluated using average annual percent change (AAPC) estimated by Joinpoint regression analysis. Results There were 268434.51 (95% UI: 229573.18, 329220.58) new PC cases, 2044006.62 (95% UI: 1749910.09, 2541958.35) PC patients, and 90275.23 (95% UI: 76005.63, 109056.31) deaths due to PC in 2019 in the WPR. The trend for DALYs (AAPC=-0.31 (95% CI=-0.35, -0.27)%, P < 0.001) decreased. With the increase in age, PC incidence (AAPC = 91.07 (95%CI = 77.40, 105.79)%, P < 0.001), mortality (AAPC = 114.62 (95%CI = 102.49, 127.48)%, P < 0.001), YLLs (AAPC = 84.23 (95%CI = 74.18, 94.86)%, P < 0.001), and DALYs (AAPC = 84.61 (95%CI = 74.25, 95.60)%, P < 0.001) rates increased notably. Our analysis shows regional differences in PC burden in the WPR from 1990 to 2019. The PC burden in most high-income countries decreased (High-Socio-Demographic-Index (SDI) countries: AAPC 95%CI=-1.46(-1.55, -1.38)%, P < 0.001). The age-standardized DALYs of PC increased in most low-income countries (Low-SDI countries: AAPC 95%CI = 0.41(0.35, 0.47)%, P < 0.001). The age-standardized DALYs of PC in middle-income countries increased or had no apparent changes, except in China (AAPC=-0.24(95% CI=-0.27, -0.2)%, P < 0.001) and Kiribati (AAPC=-0.62(95% CI = -0.83, -0.41)%, P < 0.001), which decreased. Conclusions There was a growing burden and profound imbalance in prostate cancer from 1990 to 2019 in the WPR. Our study emphasized the urgent need for tailored prevention and control strategies for PC to reduce disparities in the PC burden and promote health governance in the WPR. Public health strategies effective in high-income countries and some countries in the WPR could be used as references for developing PC prevention and intervention strategies according to local conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Disparities in the burden of prostate cancer and its trends in the Western Pacific Region, 1990-2019

Yang¹,

Zhou²,

Zhang³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Existing literature also posits that the surge in kidney cancer incidence is partly attributable to the obesity epidemic 28 and the growing prevalence of type 2 diabetes 29 . The Global Burden of Diseases Study 2019 have reported an elevation in the ASIR for kidney, bladder, prostate, and testicular cancers over the period from 1990 to 2019 by 29.1%, 4.0%, 22.0%, and 45.5%, respectively 30 . The analysis of kidney cancer incidence trends based on histological subtypes revealed notable patterns over the 2000-2019 period.…”

Section: Histological Subtypesmentioning

confidence: 99%

A population-based study on incidence trends of kidney and renal pelvis cancers in the United States over 2000–2020

Mousavi,

Najafi,

Aslani

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Cancers of the kidney and renal pelvis are among the most prevalent types of urinary cancers. We aimed to outline the incidence trends of kidney and renal pelvis cancers by age, sex, race/ethnicity, and histology in the United States (US) from 2000 to 2020. The data was obtained from the Surveillance, Epidemiology, and End Results (SEER) 22 database. The identification of patients with kidney and renal pelvis cancers with morphologies of renal cell carcinoma, nephroblastoma, sarcoma, and neuroendocrine tumor was conducted utilizing the International Classification of Diseases for Oncology version 3. The average annual percent change (AAPC) were presented. All estimates were given in the form of counts and delayed age-standardized incidence rates (ASIRs) per 100,000 people. From 2000 to 2019, a total of 490,481 cases of kidney and renal pelvic cancer were recorded across all age groups in the US. The majority of them were among Non-Hispanic Whites (NHWs) (69.75%) and those aged 55–69 years (39.96%). The ASIRs per 100,000 for kidney and pelvis cancers were 22.03 for men and 11.14 for women. Non-Hispanic Black men had the highest ASIR (24.53 [24.24, 24.81]), and increase in ASIR over the 2000–2019 period (AAPC: 2.19% [1.84, 2.84]). There was a noticeable increase in incidence of kidney and renal pelvis cancers. Individuals aged 70–84 years had the highest ASIR for kidney and renal pelvis cancers. The COVID-19 era has resulted in a significant reduction in incidence rates across all demographics.

show abstract

“…The changes in exposure to risk factors affect the burden of KC in recent years 12 . Assessing differences in health outcomes and risk factors influencing them over time and, also comparing statistics at different time points can be helpful for planning to reduce the burden of KC.…”

Section: Introductionmentioning

confidence: 99%

Decomposing difference in the kidney cancer burden measures between 1990 and 2019 based on the global burden of disease study

Ayubi,

Shahbazi,

Khazaei

2024

Sci Rep

View full text Add to dashboard Cite

The kidney cancer (KC) burden measures have changed dramatically in recent years due to changes in exposure to the determinants over time. We aimed to decompose the difference in the KC burden measures between 1990 and 2019. This ecological study included data on the KC burden measures as well as socio-demographic index (SDI), behavioral, dietary, and metabolic risk factors from the global burden of disease study. Non-linear multivariate decomposition analysis was applied to decompose the difference in the burden of KC. Globally, ASIR, ASMR, and ASDR of KC increased from 2.88 to 4.37, from 1.70 to 2.16, and from 46.13 to 54.96 per 100,000 people between 1990 and 2019, respectively. The global burden of KC was more concentrated in developed countries. From 1990 to 2019, the burden of KC has increased the most in Eastern European countries. More than 70% of the difference in the KC burden measures between 1990 and 2019 was due to changes in exposure to the risk factors over time. The SDI, high body mass index (BMI), and alcohol use had the greatest contribution to the difference in the KC burden measures. Changes in characteristics over time, including SDI, high BMI, and alcohol consumption, appear to be important in the evolving landscape of KC worldwide. This finding may help policymakers design policies and implement prevention programs to control and manage KC.

show abstract

Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: Systematic analysis for the Global Burden of Disease Study 2019

Cited by 25 publications

References 29 publications

Disparities in the burden of prostate cancer and its trends in the Western Pacific Region, 1990-2019

Disparities in the burden of prostate cancer and its trends in the Western Pacific Region, 1990-2019

A population-based study on incidence trends of kidney and renal pelvis cancers in the United States over 2000–2020

Decomposing difference in the kidney cancer burden measures between 1990 and 2019 based on the global burden of disease study

Contact Info

Product

Resources

About